REG - AstraZeneca PLC - Annual Financial Report <Origin Href="QuoteRef">AZN.L</Origin> - Part 29
08/03/2016 12:10
- Part 29: For the preceding part double click ID:nRSH4027RB
product quality failure or regulatory agency compliance action such as
licence withdrawal, product recall or product seizure.> Other
manufacturing or distribution problems, including changes in
manufacturing production sites, limits to manufacturing capacity due to
regulatory requirements, changes in the types of products produced, or
physical limitations or other business interruptions that could impact
continuous supply. Reliance on third party goods and services
We increasingly rely on third parties for the timely supply of goods, Third party supply failure could lead to significant delays and/or difficulties in obtaining goods and services on commercially acceptable terms and/or adversely affect AstraZeneca's reputation. This may materially adversely affect our business, financial condition or results of operations.Loss of access to sufficient sources of key goods and biological materials or services may interrupt or prevent planned research activities and/or increase our costs. Further information is contained in Working with suppliers in Manufacturing and Supply on page 47. ImpactSlight variations in any part of the manufacturing process or components may lead to a product that does not meet its stringent design specifications. Failure to meet these specifications may lead to recalls, spoilage, drug product shortages, regulatory action and/or reputational harm.
such as raw materials (for example, the API in some of our medicines),
equipment, formulated drugs and packaging, and services, all of which are
key to our operations. Many of these goods are difficult to substitute in
a timely manner or at all.Unexpected events and/or events beyond our
- More to follow, for following part double click ID:nRSH4027RDRecent news on AstraZeneca
See all newsRCS - LHH - LHH, EZRA's AI Leadership Transformation Program
AnnouncementREG - AstraZeneca PLC - Baxdrostat met primary endpoint in Bax24 Ph3 trial
AnnouncementREG - AstraZeneca PLC - Datroway improved OS and PFS in TROPION-Breast02
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Enhertu improved IDFS in early BC in DB-05
Announcement